Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003340 · ClinicalTrials.gov registry record · Phase 2
Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia
A Phase 2 study of Leukemia, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00003340: Completed Phase 2 study of Leukemia, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT00003340 is a Phase 2 study of Leukemia that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003340, a Phase 2 study of Leukemia, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cyclophosphamide plus topotecan in treating patients who have refractory or relapsed acute myelogenous leukemia.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG topotecan hydrochloride
Study Locations (1)
Maryland
- Johns Hopkins Oncology Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-11 |
| Est. Completion | 2000-02 |
| Phase | Phase 2 |
What the finished NCT00003340 record still lists
NCT00003340 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 2 interventions - of which cyclophosphamide is the first listed.
NCT00003340 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00003340 about?
NCT00003340 is a clinical study titled "Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cyclophosphamide plus topotecan in treating patients who have refract...
What is the current status of trial NCT00003340?
This trial is currently completed. It is a Phase 2 study. The study started on 1997-11. Estimated completion is 2000-02.
What conditions does trial NCT00003340 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00003340?
The interventions under investigation include: cyclophosphamide (DRUG), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003340?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003340 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia